Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
about
Recent advances of novel targeted therapy in non-small cell lung cancerMutational profiling of kinases in glioblastoma.Profiling critical cancer gene mutations in clinical tumor samplesKRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinibTranslatability scoring in drug development: eight case studiesCancer pharmacogenomics: strategies and challengesDynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using Extended Range Proteomic Analysis (ERPA)FAM83A confers EGFR-TKI resistance in breast cancer cells and in miceInhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interfaceNaturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitorsDownregulation and growth inhibitory role of FHL1 in lung cancerEGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistanceProtein phosphorylation profiling using an in situ proximity ligation assay: phosphorylation of AURKA-elicited EGFR-Thr654 and EGFR-Ser1046 in lung cancer cellsPerturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanismsEpithelial membrane protein-1 is a biomarker of gefitinib resistance.Comparative analysis of cancer genes in the human and chimpanzee genomes.Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinibTrials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and FutureCell signaling by receptor tyrosine kinasesIntratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cellsEGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinibMolecular biology of lung cancerMolecular biology of lung cancer: clinical implicationsMolecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancersRetroviral oncogenes: a historical primerFrom combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathwayImpact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trialsClinical use of crizotinib for the treatment of non-small cell lung cancerCirculating tumor cells: approaches to isolation and characterizationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsIdentification and validation of oncogenes in liver cancer using an integrative oncogenomic approachPhosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitorsEML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissuesMET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibSomatic mutations affect key pathways in lung adenocarcinomaSomatic mutations of the epidermal growth factor receptor and non-small-cell lung cancerThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsInduction of cancer-specific cytotoxicity towards human prostate and skin cells using quercetin and ultrasound
P2860
Q21092930-F610CD5B-A3D7-4F53-BAC8-77F2D98E4F3FQ21261249-46F014D6-E02E-4DE4-BC1E-ED04DB54BA04Q21562343-EEC9B908-4B40-45BF-878F-41642A55E8C8Q21563446-1F3BAD60-6253-4496-BBD9-F9BCD7173453Q22241760-3EC5A4B6-B28F-42E1-8E6B-08785998B878Q24289309-6524CD05-A87C-4D91-9DEE-8AF8CCC5D030Q24294659-AC7849A2-3C10-4F6B-8DE7-2E4CA68BDFB1Q24296333-EFA65A25-20BA-4105-9DA7-DBFB6AAF4020Q24301761-BB2BC785-93B2-4C82-9A7C-46F6E52F2EA0Q24305218-9C56C3BA-C14F-419F-9A29-31C07092A284Q24307767-A4284989-84C5-47CC-B88D-FBDAFBCFAC55Q24335999-0E47813A-09EF-4EE6-841D-0A9C665DEF18Q24337213-9CF172BD-D767-4727-AF2A-F3C7D908E111Q24339394-01BA04A8-C434-42F8-8AA9-D7F6A3EE784FQ24535592-AADF3250-014A-40F5-9440-0A70133650B8Q24541311-E5439139-1858-4E19-8C5B-B5FC16BBCFC1Q24541450-ED6940C6-E9CA-4C3A-A0FB-FA39BD422B0DQ24561953-71A87238-52AA-4492-A0E6-2DC034250A47Q24564024-6AD3AA60-02C1-4334-B11C-152D1DAC8AB0Q24598357-B3CB95D6-E5CF-4E2A-9A2D-4DBC3095286BQ24603941-F2B79778-2AA1-4D62-AB6B-BAE4F5510C47Q24606177-7CC962DB-0C94-48B3-803B-8CD4357362E8Q24606677-F7AF00AE-2D20-4EA6-A91F-A584C9B818BAQ24610335-2CBD4B9F-8473-4D9A-B450-5755DF5D498DQ24611043-63BF5147-5184-4576-B275-BF6A7D4883E6Q24611142-62C3B9FD-BA47-47D1-8BEB-CFA4DF10C35EQ24621007-E11F8041-2B41-41DD-9846-59BEB26CC023Q24625201-84B52FA4-E71F-49F6-9F70-CFD419B68846Q24630466-7C1854D3-57BC-470A-9867-C2BB9B3B0DF9Q24631347-27F262A2-4FCC-406F-863F-35281624FC91Q24632064-64244D74-5C16-49C2-A48B-E2D1CD23C4F7Q24633776-87B26A79-6487-42EF-A98B-13E51B90955CQ24644787-09CAD2DF-C692-4BD9-AC76-E81CFE683C9CQ24645724-53FC88AA-77A7-4DFB-8F5B-237DBB19C3E4Q24646295-1A45C11F-1772-4F7B-80AA-A6CDDCAA6B2DQ24648102-1C4C0EE8-0757-476D-A949-AB8CE02C900BQ24648133-33A1F7CA-9B21-46AE-AF0E-7376DBB5B600Q24649549-D0CD7A6C-E06C-4E7F-9D5B-5BE171D8DE24Q24649935-D17E26BD-DEB9-40D3-9690-4780EA4D814BQ24650438-6D48607F-E63A-4A4E-A157-469239CA9CA2
P2860
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Activating mutations in the ep ...... -cell lung cancer to gefitinib
@ast
Activating mutations in the ep ...... -cell lung cancer to gefitinib
@en
Activating mutations in the ep ...... -cell lung cancer to gefitinib
@nl
type
label
Activating mutations in the ep ...... -cell lung cancer to gefitinib
@ast
Activating mutations in the ep ...... -cell lung cancer to gefitinib
@en
Activating mutations in the ep ...... -cell lung cancer to gefitinib
@nl
prefLabel
Activating mutations in the ep ...... -cell lung cancer to gefitinib
@ast
Activating mutations in the ep ...... -cell lung cancer to gefitinib
@en
Activating mutations in the ep ...... -cell lung cancer to gefitinib
@nl
P2093
P3181
P356
P1476
Activating mutations in the ep ...... -cell lung cancer to gefitinib
@en
P2093
Brian W Brannigan
Daniel A Haber
Daphne W Bell
David C Christiani
David N Louis
Frank G Haluska
Jeff Settleman
Jeffrey G Supko
Patricia L Harris
Raffaella Sordella
P304
P3181
P356
10.1056/NEJMOA040938
P407
P577
2004-05-20T00:00:00Z